Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-06

AUTHORS

Aslam H. Anis, Robert S. Hogg, Xiao-hua Wang, Benita Yip, Anita Palepu, Julio S. G. Montaner, Michael V. O’Shaughnessy, Martin T. Schechter

ABSTRACT

The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were HIV-positive men and women from the province of British Columbia, Canada, who were aged 18 years or older and had given consent to access their medical records. The study employed pharmacoeconomic modelling of drug- and hospital-utilisation patterns among a population-based cohort with free access to antiretroviral therapy. Protease inhibitor use and associated costs based on actual use in a subsequent period was modelled upon men and women who were able to maintain stable CD4+ cell counts (slope > or = 0) for at least 6 months (baseline period) with an average follow-up period of 30 months (protease-like group). A control was modelled upon individuals with declining CD4+ cell counts (slope < 0) during similar baseline and follow-up periods. The primary outcome measure was average annual incremental cost of triple drug therapy net of hospitalisation and testing costs in 1996 Canadian dollars ($Can). The utilisation pattern of drugs and hospitals was modelled from actual use among a total of 1271 individuals who were eligible for this analysis. Programme participants who gave consent to access their medical records were more likely to be men (p < 0.001), older (p < 0.020), and on antiretroviral therapy (p < 0.001) than programme participants who did not give consent. No differences were observed between the protease-like and comparison groups with respect to age (p = 0.65) and CD4+ cell count (p = 0.30) at study entry. Over a period of 1 year, the protease-like group was shown to spend less time in hospital (2.7 vs 6.6 days; p < 0.001). This difference in hospitalisation remained in multivariate models, adjusting for prior AIDS-defining illnesses and gender. The average annual incremental cost of adding a protease inhibitor to a 2-drug antiretroviral regimen was estimated to be $Can2318 per person. The cost implications of hospital stay while using a protease inhibitor drug and 2 nucleosides translated into an average annual incremental cost (savings if negative) of between -$Can4798 and -$Can2227 per person. The overall average annual incremental cost impact per person associated with triple drug therapy with a protease inhibitor varied between -$Can2288 to $Can283. Negative incremental costs imply overall savings from adopting triple combination therapy. This modelling exercise demonstrated that the cost of triple drug combination antiretroviral therapy with a protease inhibitor among HIV-positive men and women was considerably less than the expected acquisition cost of the drug alone due to hospitalisation savings in the province of British Columbia. More... »

PAGES

697-705

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00019053-199813060-00006

DOI

http://dx.doi.org/10.2165/00019053-199813060-00006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048200509

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10179705


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-HIV Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "British Columbia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost of Illness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "HIV Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of British Columbia", 
          "id": "https://www.grid.ac/institutes/grid.17091.3e", 
          "name": [
            "British Columbia Centre for Excellence in HIV/AIDS, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada", 
            "Canadian HIV Trials Network, Pharmacoeconomics Program, 620-1081 Burrard Street, V67 1Y6, Vancouver, British Columbia, Canada", 
            "Departments of Healthcare and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anis", 
        "givenName": "Aslam H.", 
        "id": "sg:person.01340462506.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340462506.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of British Columbia", 
          "id": "https://www.grid.ac/institutes/grid.17091.3e", 
          "name": [
            "British Columbia Centre for Excellence in HIV/AIDS, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada", 
            "Departments of Healthcare and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hogg", 
        "givenName": "Robert S.", 
        "id": "sg:person.01057070102.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057070102.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of British Columbia", 
          "id": "https://www.grid.ac/institutes/grid.17091.3e", 
          "name": [
            "Departments of Healthcare and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Xiao-hua", 
        "id": "sg:person.01133246574.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133246574.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "St. Paul's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416553.0", 
          "name": [
            "British Columbia Centre for Excellence in HIV/AIDS, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yip", 
        "givenName": "Benita", 
        "id": "sg:person.01160746452.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160746452.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of British Columbia", 
          "id": "https://www.grid.ac/institutes/grid.17091.3e", 
          "name": [
            "Division of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palepu", 
        "givenName": "Anita", 
        "id": "sg:person.01314120026.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314120026.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of British Columbia", 
          "id": "https://www.grid.ac/institutes/grid.17091.3e", 
          "name": [
            "British Columbia Centre for Excellence in HIV/AIDS, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada", 
            "Canadian HIV Trials Network, Pharmacoeconomics Program, 620-1081 Burrard Street, V67 1Y6, Vancouver, British Columbia, Canada", 
            "Division of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Montaner", 
        "givenName": "Julio S. G.", 
        "id": "sg:person.015212221772.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015212221772.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of British Columbia", 
          "id": "https://www.grid.ac/institutes/grid.17091.3e", 
          "name": [
            "British Columbia Centre for Excellence in HIV/AIDS, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada", 
            "Canadian HIV Trials Network, Pharmacoeconomics Program, 620-1081 Burrard Street, V67 1Y6, Vancouver, British Columbia, Canada", 
            "Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Shaughnessy", 
        "givenName": "Michael V.", 
        "id": "sg:person.0663251475.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663251475.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of British Columbia", 
          "id": "https://www.grid.ac/institutes/grid.17091.3e", 
          "name": [
            "British Columbia Centre for Excellence in HIV/AIDS, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada", 
            "Canadian HIV Trials Network, Pharmacoeconomics Program, 620-1081 Burrard Street, V67 1Y6, Vancouver, British Columbia, Canada", 
            "Departments of Healthcare and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schechter", 
        "givenName": "Martin T.", 
        "id": "sg:person.016444275112.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444275112.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.1987.03400090027009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000815761"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199712010-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003832056", 
          "https://doi.org/10.2165/00019053-199712010-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199610020-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005281811", 
          "https://doi.org/10.2165/00019053-199610020-00001"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199709113371101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017575068"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199709113371102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018259390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.1997.03540480062040", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028003169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199610020-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029089270", 
          "https://doi.org/10.2165/00019053-199610020-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.pu.14.050193.000355", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034538397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199602153340703", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037804786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199813030-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043205062", 
          "https://doi.org/10.2165/00019053-199813030-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.258.9.1143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054148326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.277.24.1962", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054161127"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00042560-199703010-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060296241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00042560-199703010-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060296241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00042560-199703010-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060296241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.272.5265.1167", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062553124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.3277273", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062603638"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2531734", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069977166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-114-9-798", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073695493"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-122-8-199504150-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073699543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-96-1-102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073739193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075422566", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077955878", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079555624", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1998-06", 
    "datePublishedReg": "1998-06-01", 
    "description": "The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were HIV-positive men and women from the province of British Columbia, Canada, who were aged 18 years or older and had given consent to access their medical records. The study employed pharmacoeconomic modelling of drug- and hospital-utilisation patterns among a population-based cohort with free access to antiretroviral therapy. Protease inhibitor use and associated costs based on actual use in a subsequent period was modelled upon men and women who were able to maintain stable CD4+ cell counts (slope > or = 0) for at least 6 months (baseline period) with an average follow-up period of 30 months (protease-like group). A control was modelled upon individuals with declining CD4+ cell counts (slope < 0) during similar baseline and follow-up periods. The primary outcome measure was average annual incremental cost of triple drug therapy net of hospitalisation and testing costs in 1996 Canadian dollars ($Can). The utilisation pattern of drugs and hospitals was modelled from actual use among a total of 1271 individuals who were eligible for this analysis. Programme participants who gave consent to access their medical records were more likely to be men (p < 0.001), older (p < 0.020), and on antiretroviral therapy (p < 0.001) than programme participants who did not give consent. No differences were observed between the protease-like and comparison groups with respect to age (p = 0.65) and CD4+ cell count (p = 0.30) at study entry. Over a period of 1 year, the protease-like group was shown to spend less time in hospital (2.7 vs 6.6 days; p < 0.001). This difference in hospitalisation remained in multivariate models, adjusting for prior AIDS-defining illnesses and gender. The average annual incremental cost of adding a protease inhibitor to a 2-drug antiretroviral regimen was estimated to be $Can2318 per person. The cost implications of hospital stay while using a protease inhibitor drug and 2 nucleosides translated into an average annual incremental cost (savings if negative) of between -$Can4798 and -$Can2227 per person. The overall average annual incremental cost impact per person associated with triple drug therapy with a protease inhibitor varied between -$Can2288 to $Can283. Negative incremental costs imply overall savings from adopting triple combination therapy. This modelling exercise demonstrated that the cost of triple drug combination antiretroviral therapy with a protease inhibitor among HIV-positive men and women was considerably less than the expected acquisition cost of the drug alone due to hospitalisation savings in the province of British Columbia.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00019053-199813060-00006", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "name": "Modelling the Potential Economic Impact of Viral Load\u2014Driven Triple Drug Combination Antiretroviral Therapy", 
    "pagination": "697-705", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e59efcbc3305a634726b43c2fc3f623e04e173d446db78ae7daa77e91cb8b280"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10179705"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9212404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00019053-199813060-00006"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048200509"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00019053-199813060-00006", 
      "https://app.dimensions.ai/details/publication/pub.1048200509"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000569.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00019053-199813060-00006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-199813060-00006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-199813060-00006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-199813060-00006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-199813060-00006'


 

This table displays all metadata directly associated to this object as RDF triples.

236 TRIPLES      21 PREDICATES      62 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00019053-199813060-00006 schema:about N708148f8fc8848df8bd197c567235c5c
2 N7bfeee6c88ca4473ab056871f9cf32ca
3 N8ad038a940794027a1c21e9a0379cfcc
4 Na24ba512e4694b38aae93327bb2cb097
5 Ncbd3e3d0847843ae823f687cb9d3614a
6 Nd41c36abae6b4b829731dce72b8bda26
7 Nd941327055e74b6b82e7a36245a0300e
8 Nda1a7e1c38414cdab080a788fbac8313
9 Ne4bfc46be9804f89aba010c118a0f677
10 Ne80d0397ff6d405f8d18ff2df35c19c1
11 Nfc768b04dedb42e4b787d3545ef3596e
12 anzsrc-for:11
13 anzsrc-for:1117
14 schema:author N0e0864719ecb45f4ae804a174446ae63
15 schema:citation sg:pub.10.2165/00019053-199610020-00001
16 sg:pub.10.2165/00019053-199610020-00002
17 sg:pub.10.2165/00019053-199712010-00006
18 sg:pub.10.2165/00019053-199813030-00007
19 https://app.dimensions.ai/details/publication/pub.1075422566
20 https://app.dimensions.ai/details/publication/pub.1077955878
21 https://app.dimensions.ai/details/publication/pub.1079555624
22 https://doi.org/10.1001/jama.1987.03400090027009
23 https://doi.org/10.1001/jama.1997.03540480062040
24 https://doi.org/10.1001/jama.258.9.1143
25 https://doi.org/10.1001/jama.277.24.1962
26 https://doi.org/10.1056/nejm199602153340703
27 https://doi.org/10.1056/nejm199709113371101
28 https://doi.org/10.1056/nejm199709113371102
29 https://doi.org/10.1097/00042560-199703010-00005
30 https://doi.org/10.1126/science.272.5265.1167
31 https://doi.org/10.1126/science.3277273
32 https://doi.org/10.1146/annurev.pu.14.050193.000355
33 https://doi.org/10.2307/2531734
34 https://doi.org/10.7326/0003-4819-114-9-798
35 https://doi.org/10.7326/0003-4819-122-8-199504150-00003
36 https://doi.org/10.7326/0003-4819-96-1-102
37 schema:datePublished 1998-06
38 schema:datePublishedReg 1998-06-01
39 schema:description The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were HIV-positive men and women from the province of British Columbia, Canada, who were aged 18 years or older and had given consent to access their medical records. The study employed pharmacoeconomic modelling of drug- and hospital-utilisation patterns among a population-based cohort with free access to antiretroviral therapy. Protease inhibitor use and associated costs based on actual use in a subsequent period was modelled upon men and women who were able to maintain stable CD4+ cell counts (slope > or = 0) for at least 6 months (baseline period) with an average follow-up period of 30 months (protease-like group). A control was modelled upon individuals with declining CD4+ cell counts (slope < 0) during similar baseline and follow-up periods. The primary outcome measure was average annual incremental cost of triple drug therapy net of hospitalisation and testing costs in 1996 Canadian dollars ($Can). The utilisation pattern of drugs and hospitals was modelled from actual use among a total of 1271 individuals who were eligible for this analysis. Programme participants who gave consent to access their medical records were more likely to be men (p < 0.001), older (p < 0.020), and on antiretroviral therapy (p < 0.001) than programme participants who did not give consent. No differences were observed between the protease-like and comparison groups with respect to age (p = 0.65) and CD4+ cell count (p = 0.30) at study entry. Over a period of 1 year, the protease-like group was shown to spend less time in hospital (2.7 vs 6.6 days; p < 0.001). This difference in hospitalisation remained in multivariate models, adjusting for prior AIDS-defining illnesses and gender. The average annual incremental cost of adding a protease inhibitor to a 2-drug antiretroviral regimen was estimated to be $Can2318 per person. The cost implications of hospital stay while using a protease inhibitor drug and 2 nucleosides translated into an average annual incremental cost (savings if negative) of between -$Can4798 and -$Can2227 per person. The overall average annual incremental cost impact per person associated with triple drug therapy with a protease inhibitor varied between -$Can2288 to $Can283. Negative incremental costs imply overall savings from adopting triple combination therapy. This modelling exercise demonstrated that the cost of triple drug combination antiretroviral therapy with a protease inhibitor among HIV-positive men and women was considerably less than the expected acquisition cost of the drug alone due to hospitalisation savings in the province of British Columbia.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf N137d4427e87f4abfb99f51272700ee55
44 N6fc788f433154de3b06e7aa3d880d8a3
45 sg:journal.1102812
46 schema:name Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy
47 schema:pagination 697-705
48 schema:productId N544288f529a64d16b106af9ca4d23fc0
49 N545645c6f02b45018b59db97f1c1e95e
50 N665d9748171345c0b9927ba4f4ceea35
51 Nbd348971a18745b298f8c86704f1a964
52 Nd086702d3da74687a0619cd72036ea00
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048200509
54 https://doi.org/10.2165/00019053-199813060-00006
55 schema:sdDatePublished 2019-04-10T19:17
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher Nfacd0680a13d49b89089c5f49e4e3dd0
58 schema:url http://link.springer.com/10.2165/00019053-199813060-00006
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N05913b95c4b348b6b31f74ccc5f3304a rdf:first sg:person.0663251475.19
63 rdf:rest N72f24b6c625d453e8e1156de9e3c5000
64 N0e0864719ecb45f4ae804a174446ae63 rdf:first sg:person.01340462506.44
65 rdf:rest N5392ca15bfb6433ab79edc3b8e033655
66 N137d4427e87f4abfb99f51272700ee55 schema:issueNumber 6
67 rdf:type schema:PublicationIssue
68 N5392ca15bfb6433ab79edc3b8e033655 rdf:first sg:person.01057070102.49
69 rdf:rest Na0aa671cb1ec4923be3463db6704cc0d
70 N544288f529a64d16b106af9ca4d23fc0 schema:name dimensions_id
71 schema:value pub.1048200509
72 rdf:type schema:PropertyValue
73 N545645c6f02b45018b59db97f1c1e95e schema:name doi
74 schema:value 10.2165/00019053-199813060-00006
75 rdf:type schema:PropertyValue
76 N665d9748171345c0b9927ba4f4ceea35 schema:name readcube_id
77 schema:value e59efcbc3305a634726b43c2fc3f623e04e173d446db78ae7daa77e91cb8b280
78 rdf:type schema:PropertyValue
79 N6fc788f433154de3b06e7aa3d880d8a3 schema:volumeNumber 13
80 rdf:type schema:PublicationVolume
81 N708148f8fc8848df8bd197c567235c5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Cost of Illness
83 rdf:type schema:DefinedTerm
84 N72f24b6c625d453e8e1156de9e3c5000 rdf:first sg:person.016444275112.20
85 rdf:rest rdf:nil
86 N7bfeee6c88ca4473ab056871f9cf32ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Drug Combinations
88 rdf:type schema:DefinedTerm
89 N8ad038a940794027a1c21e9a0379cfcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Models, Economic
91 rdf:type schema:DefinedTerm
92 N9e89d91481ab4600ab7a7ac9d9eae2d8 rdf:first sg:person.01160746452.90
93 rdf:rest Ne4c25799a83d4523a05c63a43569b230
94 Na0aa671cb1ec4923be3463db6704cc0d rdf:first sg:person.01133246574.60
95 rdf:rest N9e89d91481ab4600ab7a7ac9d9eae2d8
96 Na24ba512e4694b38aae93327bb2cb097 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Drug Costs
98 rdf:type schema:DefinedTerm
99 Nbd348971a18745b298f8c86704f1a964 schema:name nlm_unique_id
100 schema:value 9212404
101 rdf:type schema:PropertyValue
102 Ncbd3e3d0847843ae823f687cb9d3614a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Male
104 rdf:type schema:DefinedTerm
105 Nd086702d3da74687a0619cd72036ea00 schema:name pubmed_id
106 schema:value 10179705
107 rdf:type schema:PropertyValue
108 Nd41c36abae6b4b829731dce72b8bda26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name British Columbia
110 rdf:type schema:DefinedTerm
111 Nd941327055e74b6b82e7a36245a0300e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Humans
113 rdf:type schema:DefinedTerm
114 Nda1a7e1c38414cdab080a788fbac8313 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Anti-HIV Agents
116 rdf:type schema:DefinedTerm
117 Ne4bfc46be9804f89aba010c118a0f677 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Adult
119 rdf:type schema:DefinedTerm
120 Ne4c25799a83d4523a05c63a43569b230 rdf:first sg:person.01314120026.59
121 rdf:rest Nf1c9b0bcc0684b689ecd374ff1d9d980
122 Ne80d0397ff6d405f8d18ff2df35c19c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Female
124 rdf:type schema:DefinedTerm
125 Nf1c9b0bcc0684b689ecd374ff1d9d980 rdf:first sg:person.015212221772.29
126 rdf:rest N05913b95c4b348b6b31f74ccc5f3304a
127 Nfacd0680a13d49b89089c5f49e4e3dd0 schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 Nfc768b04dedb42e4b787d3545ef3596e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name HIV Infections
131 rdf:type schema:DefinedTerm
132 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
133 schema:name Medical and Health Sciences
134 rdf:type schema:DefinedTerm
135 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
136 schema:name Public Health and Health Services
137 rdf:type schema:DefinedTerm
138 sg:journal.1102812 schema:issn 1170-7690
139 1179-2027
140 schema:name PharmacoEconomics
141 rdf:type schema:Periodical
142 sg:person.01057070102.49 schema:affiliation https://www.grid.ac/institutes/grid.17091.3e
143 schema:familyName Hogg
144 schema:givenName Robert S.
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057070102.49
146 rdf:type schema:Person
147 sg:person.01133246574.60 schema:affiliation https://www.grid.ac/institutes/grid.17091.3e
148 schema:familyName Wang
149 schema:givenName Xiao-hua
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133246574.60
151 rdf:type schema:Person
152 sg:person.01160746452.90 schema:affiliation https://www.grid.ac/institutes/grid.416553.0
153 schema:familyName Yip
154 schema:givenName Benita
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160746452.90
156 rdf:type schema:Person
157 sg:person.01314120026.59 schema:affiliation https://www.grid.ac/institutes/grid.17091.3e
158 schema:familyName Palepu
159 schema:givenName Anita
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314120026.59
161 rdf:type schema:Person
162 sg:person.01340462506.44 schema:affiliation https://www.grid.ac/institutes/grid.17091.3e
163 schema:familyName Anis
164 schema:givenName Aslam H.
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340462506.44
166 rdf:type schema:Person
167 sg:person.015212221772.29 schema:affiliation https://www.grid.ac/institutes/grid.17091.3e
168 schema:familyName Montaner
169 schema:givenName Julio S. G.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015212221772.29
171 rdf:type schema:Person
172 sg:person.016444275112.20 schema:affiliation https://www.grid.ac/institutes/grid.17091.3e
173 schema:familyName Schechter
174 schema:givenName Martin T.
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016444275112.20
176 rdf:type schema:Person
177 sg:person.0663251475.19 schema:affiliation https://www.grid.ac/institutes/grid.17091.3e
178 schema:familyName O’Shaughnessy
179 schema:givenName Michael V.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663251475.19
181 rdf:type schema:Person
182 sg:pub.10.2165/00019053-199610020-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005281811
183 https://doi.org/10.2165/00019053-199610020-00001
184 rdf:type schema:CreativeWork
185 sg:pub.10.2165/00019053-199610020-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029089270
186 https://doi.org/10.2165/00019053-199610020-00002
187 rdf:type schema:CreativeWork
188 sg:pub.10.2165/00019053-199712010-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003832056
189 https://doi.org/10.2165/00019053-199712010-00006
190 rdf:type schema:CreativeWork
191 sg:pub.10.2165/00019053-199813030-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043205062
192 https://doi.org/10.2165/00019053-199813030-00007
193 rdf:type schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1075422566 schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1077955878 schema:CreativeWork
196 https://app.dimensions.ai/details/publication/pub.1079555624 schema:CreativeWork
197 https://doi.org/10.1001/jama.1987.03400090027009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000815761
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1001/jama.1997.03540480062040 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028003169
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1001/jama.258.9.1143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054148326
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1001/jama.277.24.1962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054161127
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1056/nejm199602153340703 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037804786
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1056/nejm199709113371101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017575068
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejm199709113371102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018259390
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1097/00042560-199703010-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060296241
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1126/science.272.5265.1167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062553124
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1126/science.3277273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062603638
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1146/annurev.pu.14.050193.000355 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034538397
218 rdf:type schema:CreativeWork
219 https://doi.org/10.2307/2531734 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069977166
220 rdf:type schema:CreativeWork
221 https://doi.org/10.7326/0003-4819-114-9-798 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073695493
222 rdf:type schema:CreativeWork
223 https://doi.org/10.7326/0003-4819-122-8-199504150-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073699543
224 rdf:type schema:CreativeWork
225 https://doi.org/10.7326/0003-4819-96-1-102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073739193
226 rdf:type schema:CreativeWork
227 https://www.grid.ac/institutes/grid.17091.3e schema:alternateName University of British Columbia
228 schema:name British Columbia Centre for Excellence in HIV/AIDS, St Paul’s Hospital, Vancouver, British Columbia, Canada
229 Canadian HIV Trials Network, Pharmacoeconomics Program, 620-1081 Burrard Street, V67 1Y6, Vancouver, British Columbia, Canada
230 Department of Pathology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
231 Departments of Healthcare and Epidemiology, University of British Columbia, Vancouver, British Columbia, Canada
232 Division of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada
233 rdf:type schema:Organization
234 https://www.grid.ac/institutes/grid.416553.0 schema:alternateName St. Paul's Hospital
235 schema:name British Columbia Centre for Excellence in HIV/AIDS, St Paul’s Hospital, Vancouver, British Columbia, Canada
236 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...